Clinical trials: Beta-Amyloid
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Chronic Plaque Psoriasis
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
- Trial name
- DERMIS-OLE (NCT04286607)
- Testing
- Topical roflumilast
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 337 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05600036
- Testing
- ESK-001
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 228 people
- Sponsor
- Alumis Inc
Denture Stomatitis
The Effect of Palatal Brushing on Denture Stomatitis
Palatal brushing has several advantages including removal of debris and stimulation of blood flow and saliva, which may help to prevent or treat oral diseases, such as denture-related stomatitis in complete denture wearers.
- Trial name
- NCT01643876
- Testing
- Palatal brushing
- Where
- 2 sites in Brazil, Canada
- Volunteers
- 48 people
- Sponsor
- Université de Montréal
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic…
- Trial name
- NCT02325219
- Testing
- CNTO 1959 50 mg, CTNO 1959 100 mg
- Where
- 27 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Peripheral Arterial Disease
Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease
The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the treatment of patients with lower extremity vascular disease with chronic total occlusions.
- Trial name
- NCT02653456
- Testing
- RA-308 Excimer Laser and DABRA Catheter
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Ra Medical Systems
Psoriasis
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- NCT04908475
- Testing
- Risankizumab, Apremilast
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 352 people
- Sponsor
- AbbVie
Coronary Artery Disease, Myocardial Infarction
Prediction of Recurrent Events With 18F-Fluoride
This is a multi-centre observational study. It will make use of the positron emission tomography (PET) tracer 18F-sodium fluoride (18F-NaF) as a marker of coronary plaque vulnerability to detect culprit and non-culprit unstable…
- Trial name
- PREFFIR (NCT02278211)
- Where
- United Kingdom
- Volunteers
- 995 people
- Sponsor
- University of Edinburgh
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Psoriasis, Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
- Trial name
- CIMPASI-1 (NCT02326298)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 234 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
- Trial name
- NCT02932878
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Amyloid-beta
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
- Trial name
- NCT02063217
- Testing
- Sodium Oxybate, Sleep deprivation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Plaque Psoriasis
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and…
- Trial name
- NCT03992261
- Testing
- Halobetasol Topical Foam
- Where
- 11 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Mayne Pharma International Pty Ltd
Dental Caries
Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes
The purpose of this study is to investigate the efficacy of different sodium fluoride (NaF) containing toothpastes in prevention of dental caries.
- Trial name
- NCT00708305
- Testing
- Sodium Fluoride (NaF)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline